Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03526887
Title Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Spanish Lung Cancer Group
Indications

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST